CHANGE MY LOCATION
Business News
Gustav swells to dangerous Cat 3 storm off Cuba- Gustav swelled to a fearsome Category 3 hurricane with winds of 120 mph as it shrieked toward the heartland of Cuba's cigar industry Saturday on a track to hit the U.S. Gulf Coast three years after Hurricane Katrina.
- As city officials detailed plans for an evacuation that could be called over the weekend, some residents weren't waiting to be told to leave.
McCain makes history with choice of running mate- In two short years, Sarah Palin moved from small-town mayor with a taste for mooseburgers to the governor's office and now - making history - to John McCain's side as the first female running mate on a Republican presidential ticket.
Pressure grows on Thai prime minister to resign- Thailand's prime minister vowed Saturday that he would not resign even as pressure mounted with anti-government protesters occupying his headquarters for a fifth day Saturday and disrupting rail and air service.
- The top U.S. commander in Iraq, Gen. David Petraeus, has given his military superiors and Defense Secretary Robert Gates his initial recommendation on when to resume a U.S. troop withdrawal and at what pace, a senior military officer close to the process said Friday.
Obama's speech seen by 38 million-plus viewers- Barack Obama's audience for his acceptance speech likely topped 40 million people, and the Democratic gathering that nominated him was a more popular television event than any other political convention in history.
- The Maine artist who brought LOVE to the world is doing the same with HOPE.
- In a return to the public stage, John Edwards has confirmed plans to talk politics a month after admitting to an extramarital affair. But his wife won't be at his side.
Georgia to sever diplomatic ties with Russia- Georgia said Friday it will sever diplomatic ties with Moscow to protest the presence of Russian troops on its territory. Russia criticized the move, pinning blame for a breakdown in relations on Tbilisi.
Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer
The study, conducted in the US,
"Given the variety of cancer drugs available today, the ability to monitor CTCs in conjunction with radiological assessment may help physicians and patients make more informed and timely treatment decisions," said lead investigator and author
These findings were included in a report titled, "Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients with Metastatic Colorectal Cancer," which summarizes data from a prospective trial involving 430 colorectal cancer patients at 55 clinical centers using the CellSearch System to count CTCs. Researchers counted the number of circulating tumor cells in the peripheral blood of patients at baseline and after starting first-, second-, or third-line therapy.
The CellSearch(TM) System is the first diagnostic test to automate the process of identifying and counting circulating tumor cells (CTCs) in a blood sample. This system helps physicians to predict disease progression and patient survival any time during therapy through its ability to locate minute numbers of circulating tumor cells in the approximately 40 billion cells contained in a 7.5 ml sample of blood - an achievement never before documented in any diagnostic tool.
"Clinical studies continue to validate the significance of circulating tumor cells in treating patients with metastatic breast, colorectal or prostate cancer," said
According to the American Cancer Society, colorectal cancer claims approximately 55,000 lives each year, the vast majority of which are a result of recurrent metastatic disease. Metastatic colorectal cancer occurs when tumor cells spread to other locations in the body and grow. Although there are several options for the treatment of metastatic colorectal cancer, oncologists often have to wait several months before they can determine if a specific treatment is beneficial to the patient.
The U.S. Food and Drug Administration (FDA) first cleared The CellSearch(TM) System in
*Dr.
About Veridex
Veridex, LLC, a Johnson & Johnson company, is an organization dedicated to providing physicians with high-value in vitro diagnostic oncology products. Veridex's products may significantly benefit patients through earlier disease detection and may enable personalized strategies to help improve patient management and outcomes. For more information, please visit www.veridex.com.
|
|
More Business_and_Finance Releases
(CME): CME Group Revised Labor Day Holiday Hours for NYMEX Energy Products
